ADC Therapeutics SA 2025-2026 Proxy Voting Records

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Ameet Mallik be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Ameet Mallik”): 65,133,390 for, 387,036 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,550,482 for, 597 against.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Jean-Pierre Bizzari be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Jean-Pierre Bizzari”): 63,631,611 for, 1,852,731 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,241,928 for, 283,831 against, 25,320 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Timothy Coughlin be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Timothy Coughlin”): 65,198,947 for, 327,049 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,551,079 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Tyrell Rivers be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Tyrell Rivers”): 64,796,462 for, 729,534 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,550,482 for, 597 against.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Viviane Monges be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Viviane Monges”): 64,918,973 for, 556,772 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,395,034 for, 130,725 against, 25,320 abstained.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Ron Squerer be reelected as the chair of the board of directors and a director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

ADC Therapeutics SA’s own tally for this item (“Elect Director: Ron Squarer”): 65,109,377 for, 416,194 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal #5 : Reelecting directors The shareholders reelected the following directors for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,543,623 for, 7,456 against.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Discharging the members of the Board of Directors and the Executive Committee from Liability for the year ended December 31, 2025. The Board of Directors proposes that the members of the Board of Directors and the Executive Committee be discharged from liability for the year ended December 31, 2025.

ADC Therapeutics SA’s own tally for this item (“3. Discharging the members of the board of directors and the executive committee from liability”): 63,695,590 for, 86,523 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #3 : Discharging the members of the board of directors and the executive committee from liability The shareholders approved that the members of the board of directors and the executive committee be discharged from liability for the year ended December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 35 asset managers below reported 11,520,904 for.

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Peter Hug be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

The 24 asset managers below reported 1,793,316 for, 130,128 against, 25,320 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Robert Azelby be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

The 24 asset managers below reported 1,948,764 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Board of Directors: The board of directors proposes that Victor Sandor be reelected as director for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of shareholders.

The 24 asset managers below reported 1,948,764 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The board of directors proposes that Peter Hug be reelected as a member of the Compensation Committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of Shareholders.

The 24 asset managers below reported 1,793,316 for, 130,128 against, 25,320 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The board of directors proposes that Robert Azelby be reelected as a member of the compensation committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of Shareholders.

The 24 asset managers below reported 1,948,764 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Reelecting nominees to the Compensation Committee of the Board of Directors: The board of directors proposes that Victor Sandor be reelected as a member of the Compensation Committee for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of Shareholders.

The 24 asset managers below reported 1,948,764 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT A NEW ARTICLE 4D BE INTRODUCED IN THE ARTICLES OF ASSOCIATION REGARDING A CONDITIONAL SHARE CAPITAL BASED ON THE CAPITAL RANGE, AND THAT ARTICLE 4A BE AMENDED ACCORDINGLY, TO PROVIDE FOR THE ISSUANCE OF UP TO 64,863,182 COMMON SHARES (CHF 5,189,054.56).

The 31 asset managers below reported 12,577,687 for, 1,152,359 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT THE AMENDMENTS TO ARTICLE 4B PARAGRAPH 1 OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY'S CONDITIONAL SHARE CAPITAL FOR EMPLOYEE PARTICIPATION FROM 9,887,629 COMMON SHARES (CHF 791,010.32) TO 16,836,253 COMMON SHARES (CHF 1,346,900.24) BE APPROVED.

The 31 asset managers below reported 6,800,996 for, 1,227,395 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT THE AMENDMENTS TO ARTICLE 4C PARAGRAPH 1 OF THE ARTICLES OF ASSOCIATION TO INCREASE THE COMPANY'S CONDITIONAL SHARE CAPITAL FOR FINANCING, ACQUISITIONS AND OTHER PURPOSES FROM 38,026,929 COMMON SHARES (CHF 3,042,154.32) TO 48,026,929 COMMON SHARES (CHF 3,842,154.32) BE APPROVED.

The 31 asset managers below reported 6,876,032 for, 1,152,359 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 31 asset managers. See all 31 in the interactive database.

Description as filed by funds: Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company's capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range. The Board of Directors proposes that the amendments to article 4a paragraph 1 of the articles of association to increase the Company's capital range from CHF 8,375,974.48 (lower limit) and CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) and CHF 15,567,163.68 (upper limit) be approved.

The 25 asset managers below reported 6,875,828 for, 774,591 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: Approving the appropriation of the financial results for the year ended December 31, 2025 by carrying forward the loss resulting from such year. The Board of Directors proposes that the net loss for the year ended December 31, 2025, be carried forward.

ADC Therapeutics SA’s own tally for this item (“4. Approving the appropriation of the financial results”): 79,774,946 for, 8,511 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #4 : Approving the appropriation of the financial results The shareholders approved that the net loss for the year ended December 31, 2025 be carried forward.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,551,079 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting PHC Notaires, in Lausanne, Switzerland, as the Independent Proxy The Board of Directors proposes that PHC Notaires, in Lausanne, Switzerland be reelected as the Independent Proxy for a one-year term, beginning as of the Annual Meeting and ending at the closing of the 2027 annual general meeting of Shareholders.

ADC Therapeutics SA’s own tally for this item (“7. Reelecting the Independent Proxy”): 79,756,534 for, 17,712 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,551,079 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

The 26 asset managers below reported 393 for, 7,680,201 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 26 asset managers. See all 26 in the interactive database.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT THE MAXIMUM AGGREGATE AMOUNT OF VARIABLE COMPENSATION FOR THE MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE YEAR ENDING DECEMBER 31, 2026, BE SET AT $5,500,000.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 31 managers: 8,028,391 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 5 managers: 87,224 for.

Description as filed by funds: Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The Board of Directors proposes that an amendment to increase the number of shares authorized under 2019 Equity Incentive Plan be approved.

ADC Therapeutics SA’s own tally for this item (“11. Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan”): 46,624,648 for, 18,904,924 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #11 : Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The shareholders approved an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 35 asset managers below reported 5,701,655 for, 5,819,249 against.

Showing the 25 largest of 35 asset managers. See all 35 in the interactive database.

Description as filed by funds: Approving, on an advisory basis under U.S. law, the compensation paid to our Named Executive Officers The Board of Directors proposes that the following proposal: "RESOLVED, that the Company's Shareholders approve, on an advisory basis, the compensation of the Company's Named Executive Officers, as disclosed in "Executive Compensation" and the related compensation tables and narrative disclosure in this proxy statement", be approved.

ADC Therapeutics SA’s own tally for this item (“10. Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers”): 64,172,306 for, 1,271,205 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #10 : Approving, on an advisory basis under U.S. law, the compensation paid to the named executive officers The shareholders approved, on an advisory basis under U.S. law, the compensation of the Company's named executive officers, as disclosed in "Executive Compensation" and the related c…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 36 managers: 11,551,079 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 97 managers: 32,774,942 for, 745,981 against, 3,800,194 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Approving, on an advisory basis under Swiss law, the Company's Compensation Report for the year ended December 31, 2025. The Board of Directors proposes that the Company's Compensation report for the year ended December 31, 2025, be approved in a non-binding advisory vote.

ADC Therapeutics SA’s own tally for this item (“2. Approving, on an advisory basis under Swiss law, the compensation report”): 64,289,299 for, 1,242,782 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #2 : Approving, on an advisory basis under Swiss law, the compensation report The shareholders approved, in a non-binding advisory vote, the compensation report for the year ended December 31, 2025.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 36 managers: 11,551,079 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 5 managers: 2,800,683 for, 1,199 against.

Description as filed by funds: THE BOARD OF DIRECTORS PROPOSES THAT THE MAXIMUM AGGREGATE AMOUNT OF FIXED COMPENSATION FOR THE MEMBERS OF THE EXECUTIVE COMMITTEE FOR THE YEAR ENDING DECEMBER 31, 2027, BE SET AT $2,600,000.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 31 managers: 8,028,391 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 5 managers: 87,224 for.

Description as filed by funds: Approving, on a binding basis under Swiss law, the compensation of the Board of Directors and the Executive Committee The Board of Directors proposes that the maximum aggregate amount of compensation for the members of the Board of Directors for the period between the Annual Meeting and the 2027 annual general meeting of Shareholders be set at $2,500,000.

ADC Therapeutics SA’s own tally for this item (“9. Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee”): 48,456,972 for, 16,977,874 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #9 : Approving, on a binding basis under Swiss law, the compensation of the board of directors and the executive committee The shareholders approved, on a binding basis under Swiss law, that (i) the maximum aggregate amount of compensation for the members of the board of directors for the …”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ADC Therapeutics SA’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Approving, on a binding basis under Swiss law, the compensation of the Board of Directors and the Executive Committee - Proposal #9b: The board of directors proposes that the maximum aggregate amount of fixed compensation for the members of the executive committee for the year ending December 31, 20” (4 managers, 3,492,513 for); “Approving, on a binding basis under Swiss law, the compensation of the Board of Directors and the Executive Committee - Proposal #9c: The board of directors proposes that the maximum aggregate amount of variable compensation for the members of the executive committee for the year ending December 31,” (4 managers, 3,492,513 for).

The 29 asset managers below reported 6,999,097 for, 4,143,835 against.

Showing the 25 largest of 29 asset managers. See all 29 in the interactive database.

Description as filed by funds: Approving the Company's management report, annual financial statements and consolidated financial statements for the year ended December 31, 2025 and acknowledging the Auditors' Reports for the year ended December 31, 2025. The Board of Directors proposes that the Management Report, the Annual Financial Statements and the Consolidated Financial Statements for the year ended December 31, 2025, be approved and the Auditors' Reports for the year ended December 31, 2025, be acknowledged.

ADC Therapeutics SA’s own tally for this item (“1. Approving the management report, annual financial statements and consolidated financial statements”): 79,705,454 for, 5,910 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal #1 : Approving the management report, annual financial statements and consolidated financial statements The shareholders approved the management report, the annual financial statements and the consolidated financial statements for the year ended December 31, 2025 and acknowledged the audit…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,551,079 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

Description as filed by funds: Reelecting PricewaterhouseCoopers SA as the auditors The Board of Directors proposes that PricewaterhouseCoopers SA be reelected as the statutory auditor and independent registered public accounting firm for the year ending December 31, 2026.

ADC Therapeutics SA’s own tally for this item (“8. Reelecting the auditors”): 79,747,180 for, 31,325 against, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 11,551,079 for.

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.